|
Active substance |
zanubrutinib |
|
Holder |
BeiGene France |
|
Status |
closed |
|
Indication |
for the treatment of adult patients with Marginal Zone Lymphoma (MZL) who have received at least one prior anti-CD20 based therapy, and for whom there are no available clinical studies Titulaire : BeiGene France . |
|
Public documents |
|
|
Dernière mise à jour |
23/02/2024 |
Brukinsa
Last updated on 10/09/2024